Loading...
Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy
MUC1 is an attractive target for cancer vaccines as a result of its over-expression and aberrant glycosylation pattern on many tumor cells. However, the low immunogenicity of MUC1 and immune tolerance have limited its application. Herein, we designed MUC1-based tricomponent antitumor vaccines adjuva...
Na minha lista:
| Udgivet i: | Medchemcomm |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Royal Society of Chemistry
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6991171/ https://ncbi.nlm.nih.gov/pubmed/32133105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c9md00254e |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|